In 2008, NICE said patients would not be able to try a second anti-TNF if their first attempt at anti-TNF therapy failed.

BBC: More arthritis drugs to be made available on the NHS

Is simply making an orally available anti-TNF or anti-IL17 interesting enough?

FORBES: Innovation Snapshot: Macrocyclic drugs to unlock new therapeutic targets

In March this year, NICE said adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade) could only be used in the context of research, even for those patients who had failed on one anti-TNF.

BBC: More arthritis drugs to be made available on the NHS